Biogen and Eisai Launch Autoinjector for Early Alzheimer’s Treatment — Biogen Inc.

Event summary

Biogen and Eisai have launched the LEQEMBI IQLIK® autoinjector for initiating lecanemab therapy in early Alzheimer’s disease patients in the U.S.
The autoinjector offers a convenient alternative to intravenous (IV) dosing, with a once-weekly 500 mg dose administered via two consecutive 250 mg injections.
The new delivery method aims to reduce healthcare resource use and increase patient convenience, allowing for at-home administration.
LEQEMBI IQLIK can also be used for maintenance dosing after 18 months of IV or subcutaneous treatment, providing flexibility in administration.
Eisai and Biogen are providing support resources, including an Instructions for Use (IFU) video, IQLIK Welcome Kit, and the LEQEMBI Companion® app.

The big picture

The launch of the LEQEMBI IQLIK autoinjector represents a strategic shift towards more convenient and flexible treatment options for early Alzheimer’s disease. This move aligns with broader industry trends towards patient-centric care and reducing the burden on healthcare systems. The ability to administer treatment at home could significantly lower barriers to initiation and continuation of therapy, potentially expanding the patient base for lecanemab.

What we're watching

Adoption Pace: The pace at which patients and healthcare providers adopt the autoinjector for initiating lecanemab therapy will be a key indicator of its success.
Regulatory Approvals: The progress of regulatory approvals for subcutaneous initiation treatment in other countries, including Japan and China, will impact the global availability of LEQEMBI IQLIK.
Competitive Dynamics: How Biogen and Eisai's move to enhance treatment convenience will affect the competitive landscape for Alzheimer’s disease treatments.